KR900017993A - 거울상 이성체 글루타르아미드 이뇨제 - Google Patents

거울상 이성체 글루타르아미드 이뇨제 Download PDF

Info

Publication number
KR900017993A
KR900017993A KR1019890006691A KR890006691A KR900017993A KR 900017993 A KR900017993 A KR 900017993A KR 1019890006691 A KR1019890006691 A KR 1019890006691A KR 890006691 A KR890006691 A KR 890006691A KR 900017993 A KR900017993 A KR 900017993A
Authority
KR
South Korea
Prior art keywords
compound
formula
ethyl
benzyl
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019890006691A
Other languages
English (en)
Other versions
KR920000561B1 (ko
Inventor
크리스토퍼 다니엘위쯔 존
트레벨얀 윌리암스 마이클
Original Assignee
원본미기재
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 화이자 인코포레이티드 filed Critical 원본미기재
Publication of KR900017993A publication Critical patent/KR900017993A/ko
Application granted granted Critical
Publication of KR920000561B1 publication Critical patent/KR920000561B1/ko
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음

Description

거울상 이성체 글루타르아미드 이뇨제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. R-거울상 이성질체가 실질적으로 유리된 일반식(Ⅱ)의 S-거울상 이성질체 화합물 및 이의 약제학적으로 허용되는 염.
    상기식에서, R 및 R4는 각각 H이거나, R 및 R4중 어느 하나는 수소이고 다른 것은 생물학적으로 불안정한 에스테르 그룹을 나타낸다.
  2. 상기 생물학적으로 불안정한 에스테르 그룹이 에틸, 벤질, 1-(2,2-디에틸부티릴옥시)에틸, 2- 에틸프로피오닐옥시메틸, 1-(2-에틸프로피오닐옥시)에틸, 1-(2,4-디메틸벤조일옥시)에틸, α-벤조일옥시벤질, 1-(벤조일옥시)에틸, 2-메틸-1-프로피오닐옥시-1-프로필, 2,4,6-프리케틸벤조일옥시메틸, 1-(2,4,6-트리메틸 벤조일옥시)에틸, 피발로일옥시메틸, 펜에틸, 펜프로필, 2,2,2-트리플루오로에틸, 1- 또는 2- 나프틸, 2,4-디메틸페닐, 4-t-부틸페닐 및 5-인다닐인 일반식(Ⅱ)의 화합물.
  3. (S)-시스-4-{1-[2-(5-인다닐옥시카보닐)-3-(2-메록시에톡시)프로필]-1-사이클로펜탄카복사미도}-1-사이클로헥산카복실산.
  4. (-)-가구-4-{1-[2-(5-인다닐옥시카보닐)-2-(2-메톡시에톡시)프로필]-1-사이클로펜탄카복사미도}-1-사이클로헥산카복실산.
  5. (S)-시스-4-{1-[2-카복시-3-(2-메록시에톡시)프로필]-1-사이클로펜탄카복사미도}-1-사이클로헥산카복실산.
  6. (+)-시스-4-{1-[2-카복시-3-(2-메록시에톡시)프로필]-1-사이클로펜탄카복사미도}-1-사이클로헥산카복실산.
  7. (a) 일반식(Ⅵ)의 S거울상 이성체 화합물을 일반식(Ⅹ)의 화합물과 커플링시키고, (b)R13및 R14중 어느 하나 또는 둘다를 제거하여 일반식(Ⅱ)의 모노-에스테르 또는 디카복실산 생물학적 수득하거나, (c)R13을 제거하고, 생성물을 에스테르화하여 생물학적으로 불한정한 에스테르 그룹을 제공하여 R14를 제거하여 R4가 H이고 R은 생물학적으로 불안정한 에스테르 그룹인 일반식(Ⅱ)의 생성물을 수득하는 단계를 포함함을 특징으로 하는, 제1항의 화합물의 제조방법.
    상기식에서, R13및 R14는 수소를 제외하고 R 및 R4에 대해 정의한 바와 같거나, 선택적으로 제거할 수 있는 카복실산 보호그룹이다.
  8. 제7항에 있어서, R13가 N-아세틸-(1R, 2S)-에페드린을 형성하고 R14가 에틸이며, 에스테르 그룹을 수소화시킨 다음 가수분해시킴으로써 제거하여 R 및 R4가 둘다 H인 일반식(Ⅱ)의 화합물을 수득하는 방법.
  9. 제7항에 있어서, R13이인다닐이고 R14가 벤질이며 언급된 벤질 그룹을 제거하여 R이 5-인다닐이고 R4가 H인 일반식(Ⅱ)의 화합물을 수득하는 방법.
  10. 제7항에 있어서, R13이3급-부틸이고 R14가 벤질이며 언급된 그룹을 제거하여 R 및 R4가 둘다 수소인 일반식(Ⅱ)의 화합물을 수득하는 방법.
  11. 제7항에 있어서, R13이3급-부틸이고 R14가 벤질이며 언급된 3급-부틸 그룹을 제거하고, 생성물을 에스테르화하여 R에 생물학적으로 불안정한 에스테르 그룹을 제공하며, 벤질 그룹을 제거하는 방법.
  12. 약제학적으로 허용되는 희석제 또는 담체와 함께, 제1항 내지 6항중 어느 한 항의 화합물 또는 이의 약제학적으로 허용되는 염을 함유함을 특징으로 하는 약제학적 조성물.
  13. 제1항 내지 6항중 어느 한 항에 있어서, 의학용으로 사용하기 위한, 특히 고혈압 및 심기능부전의 치료를위한 이뇨제로서 사용하기 위한 화합물 및 약제학적으로 허용되는 이의 염.
  14. 제7항의 일반식(Ⅳ)의 화합물.
  15. 제14항에 있어서, R13이 5-인다닐, 3급-부틸이거나 N-아세틸-(1R, 2S)-에페드린 에스테르를 형성하는 화합물.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019890006691A 1988-05-19 1989-05-19 거울상 이성체 글루타르아미드 이뇨제 Expired KR920000561B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8811873.2 1988-05-19
GB888811873A GB8811873D0 (en) 1988-05-19 1988-05-19 Therapeutic agents
US8811873.2 1988-05-19

Publications (2)

Publication Number Publication Date
KR900017993A true KR900017993A (ko) 1990-12-20
KR920000561B1 KR920000561B1 (ko) 1992-01-16

Family

ID=10637176

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890006691A Expired KR920000561B1 (ko) 1988-05-19 1989-05-19 거울상 이성체 글루타르아미드 이뇨제

Country Status (29)

Country Link
EP (1) EP0342850B1 (ko)
JP (1) JPH072699B2 (ko)
KR (1) KR920000561B1 (ko)
CN (1) CN1015361B (ko)
AT (1) ATE76399T1 (ko)
AU (1) AU602813B2 (ko)
CA (1) CA1331197C (ko)
CS (1) CS274502B2 (ko)
DD (1) DD283772A5 (ko)
DE (1) DE68901582D1 (ko)
DK (1) DK172032B1 (ko)
EG (1) EG19007A (ko)
ES (1) ES2037418T3 (ko)
FI (1) FI93541C (ko)
GB (1) GB8811873D0 (ko)
GR (1) GR3004968T3 (ko)
HU (1) HU205067B (ko)
IE (1) IE60724B1 (ko)
IL (1) IL90267A (ko)
MX (1) MX16067A (ko)
MY (1) MY104735A (ko)
NO (1) NO173647C (ko)
NZ (1) NZ229186A (ko)
PH (1) PH26740A (ko)
PL (1) PL154813B1 (ko)
PT (1) PT90584B (ko)
SU (1) SU1766251A3 (ko)
YU (1) YU47973B (ko)
ZA (1) ZA893696B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812597D0 (en) * 1988-05-27 1988-06-29 Pfizer Ltd Therapeutic agents
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
GB9000725D0 (en) * 1990-01-12 1990-03-14 Pfizer Ltd Therapeutic agents
ES2081183T3 (es) * 1993-09-22 1996-02-16 Pfizer Res & Dev Hidrogenacion.
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US8993631B2 (en) * 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
PL2887961T3 (pl) 2012-08-24 2021-11-08 Novartis Ag Inhibitory nep do leczenia chorób charakteryzujących się powiększeniem lub przebudową przedsionka
WO2017033128A1 (en) 2015-08-25 2017-03-02 Novartis Ag Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
US20180311241A1 (en) 2015-10-29 2018-11-01 Cadila Healthcare Limited Pharmaceutical synergistic combination

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제

Also Published As

Publication number Publication date
MX16067A (es) 1993-10-01
CS296589A2 (en) 1990-09-12
YU47973B (sh) 1996-08-13
DD283772A5 (de) 1990-10-24
HU205067B (en) 1992-03-30
DK240889A (da) 1989-11-20
DE68901582D1 (de) 1992-06-25
EG19007A (en) 1994-11-30
AU602813B2 (en) 1990-10-25
KR920000561B1 (ko) 1992-01-16
ATE76399T1 (de) 1992-06-15
DK172032B1 (da) 1997-09-22
ES2037418T3 (es) 1993-06-16
PT90584A (pt) 1989-11-30
IL90267A0 (en) 1989-12-15
IE60724B1 (en) 1994-08-10
NO173647B (no) 1993-10-04
NO892002L (no) 1989-11-20
HUT53596A (en) 1990-11-28
EP0342850A1 (en) 1989-11-23
ZA893696B (en) 1990-12-28
PT90584B (pt) 1994-09-30
MY104735A (en) 1994-05-31
DK240889D0 (da) 1989-05-18
JPH0222256A (ja) 1990-01-25
NO892002D0 (no) 1989-05-18
PL279491A1 (en) 1989-11-27
YU102289A (en) 1991-06-30
JPH072699B2 (ja) 1995-01-18
FI93541B (fi) 1995-01-13
GR3004968T3 (ko) 1993-04-28
GB8811873D0 (en) 1988-06-22
AU3490489A (en) 1989-11-23
FI892386A0 (fi) 1989-05-18
FI93541C (fi) 1995-04-25
CS274502B2 (en) 1991-04-11
EP0342850B1 (en) 1992-05-20
SU1766251A3 (ru) 1992-09-30
IL90267A (en) 1993-08-18
CN1015361B (zh) 1992-02-05
CA1331197C (en) 1994-08-02
IE891613L (en) 1989-11-19
FI892386L (fi) 1989-11-20
CN1037704A (zh) 1989-12-06
PH26740A (en) 1992-09-28
NO173647C (no) 1994-01-12
NZ229186A (en) 1990-10-26
PL154813B1 (en) 1991-09-30

Similar Documents

Publication Publication Date Title
KR900017993A (ko) 거울상 이성체 글루타르아미드 이뇨제
KR920012035A (ko) 치환된 피리딜-디하이드록시-헵텐 산 및 그의 염
DE3883495D1 (de) Enantiomere Derivate von Aminosäure, Verfahren zu deren Herstellung und deren therapeutische Verwendung.
KR920018011A (ko) N-아실-α-아미노산 유도체
IE43916L (en) Allenic prostaglandins
KR890006661A (ko) 치환된 α-아미노산, 그 제조방법 및 이들을 함유하는 약학 조성물
ATE57834T1 (de) Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur verhinderung oder behandlung posttraumatischer nervenschaeden nach unfallbedingten rueckenmarks- und/oder gehirntraumen.
GB1245219A (en) Amino acid derivatives
IE37392L (en) 5-amino-isophthalic acid derivatives
DE59002361D1 (de) Geschuetzte aminosaeuren und verfahren zu ihrer herstellung.
GB1225462A (ko)
FR2455047A1 (fr) Sels de 1-alkyl-9-bromo-hexahydroindoloquinolizinium, leur procede de preparation, et leur utilisation comme medicament et pour la synthese d'un ester d'acide 10-bromo vincaminique
KR920012008A (ko) 페닐알킬아미노알킬 화합물과 이들의 제법 및 이 화합물들을 포함하는 약물
AU8426191A (en) Phenylethanolamines, drugs containing these compounds, and a method of preparing them
KR900011720A (ko) 글리신 유도체 및 그의 제조방법
GB1385150A (en) Sulphur-containing ring compounds and compositions thereof
KR890701584A (ko) 20, 21-디노르에비나메닌의 신규 치환 유도체, 그의 제조 방법 및 이 방법으로 얻는 신규 중간체, 약제로서의 그의 용도 및 그를 함유하는 제약 조성물
KR860001111A (ko) 아미노 에부르난 카르복실산 유도체의 제조방법
DE69219244D1 (de) Verfahren zur Herstellung von optisch-aktiven 3-Phenylglycidsäure-Estern
FR2431482A1 (fr) Nouveaux alcanoates derives de cyclopropane utiles dans la preparation d'esters cyclopropanecarboxylates et procede pour leur preparation
KR880001561A (ko) 유효한 치료성을 갖는 신규 8-(저급알킬)비시클로[4.2.0] 옥탄 유도체
DE69412094D1 (de) Herstellung von gemischen von estern der (r)- und (s)-2-(4-alkanylphenoxy)-oder (r)- und (s)-2-(4-aroylphenoxy)propansäure
Moore Synthetic organic local anesthetics
GB1382699A (en) Amino-esters
KR910007875A (ko) 도파민 길항제로서의 벤질피롤리딘 유도체

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

FPAY Annual fee payment

Payment date: 20030109

Year of fee payment: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040117

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040117

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000